Zomedica (ZOM) Stock Price, News & Analysis

Company Overview

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.10 to $0.15
• 52-Week Range: N/A
• Volume: 790,936 shs
• Average Volume: 4.72 million shs
• Market Capitalization: $95.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

ZOM Stock Analysis - Frequently Asked Questions

How were Zomedica's earnings last quarter?

Zomedica Corp. (NYSEAMERICAN:ZOM) announced its earnings results on Thursday, November, 7th. The company reported ($0.01) earnings per share for the quarter. The business had revenue of $7 million for the quarter. Zomedica had a negative net margin of 232.88% and a negative trailing twelve-month return on equity of 12.47%.
Read the conference call transcript.

How do I buy shares of Zomedica?

Shares of ZOM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Zomedica own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zomedica investors own include Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT), Phunware (PHUN) and Inuvo (INUV).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:ZOM
• CIK: 1684144
• Web: www.zomedica.com
• Phone: 734-369-2555
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.53 million
• Net Margins: -232.88%
• Pretax Margin: -232.24%
• Return on Equity: -12.47%
• Return on Assets: -11.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.82
• Quick Ratio: 10.15

Sales & Book Value

• Annual Sales: $25.19 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.24 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 979,950,000
• Free Float: 938,890,000
• Market Cap: $95.35 million
• Optionable: Not Optionable
• Beta: 1.03